FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

68 letters match. Newest first.

  1. www.weightcrunchshop.com

    FDA warned www.weightcrunchshop.com about selling unapproved and misbranded semaglutide and oxycodone drugs to U.S. consumers online.

    High risk
  2. Eugia Pharma Specialities Limited

    FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.

    High risk
  3. Akan Biosciences, Inc.

    FDA warned Akan Biosciences over unapproved Ayama injectable and donor-screening failures.

    High risk
  4. QuVa Pharma, Inc.

    FDA warned QuVa Pharma, a sterile drug outsourcing facility in Bloomsbury, NJ, of mold in its cleanest filling area and other CGMP failures.

    High risk
  5. Intas Pharmaceuticals Limited

    FDA cited Intas Pharmaceuticals for CGMP violations, including manipulated visual inspection records and inadequate sterile-drug controls.

    High risk
  6. Sun Pharmaceutical Industries Ltd.

    FDA warns Sun Pharmaceutical over CGMP violations in sterile injectable manufacturing at its Halol, India facility.

    High risk
  7. Southern Tier Home Infusion, Inc. dba Pharmacy Innovations

    FDA warned compounding pharmacy Pharmacy Innovations that its sterile drugs were made under insanitary conditions and without valid patient prescriptions.

    High risk
  8. Baxter Healthcare Corporation

    FDA warned Baxter over CGMP violations at its India plant, including inadequate endotoxin and visual inspection investigations for sterile injectables.

    High risk
  9. Warrior Labz SARMS

    FDA warned Warrior Labz SARMS that it sells unapproved new drugs, including SARMs and injectables, with drug claims online.

    High risk
  10. North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding

    FarmaKeio, a Texas compounding pharmacy, made sterile drugs under insanitary conditions that put patients at risk.

    High risk
  11. Invitrx Therapeutics, Inc.

    Invitrx Therapeutics made unapproved umbilical cord and exosome products and had serious manufacturing deviations.

    High risk
  12. Abraxis Bioscience LLC

    FDA warned Abraxis Bioscience about repeated contamination in media fills for sterile Abraxane at its Phoenix plant.

    High risk
  13. Nephron SC Inc.

    Nephron SC's sterile drug manufacturing had unresolved cross-contamination and microbial contamination, making its drugs adulterated.

    High risk
  14. Green Wave Analytical, LLC

    FDA warned Green Wave Analytical, a contract drug testing lab, over quality violations and its denied inspection access.

    High risk
  15. Re-Gen Active Lab, Inc.

    FDA warned Re-Gen Active Lab over unapproved amniotic/umbilical cord injectables and serious sterility failures.

    High risk
  16. Hybrid Pharma, LLC

    FDA warned outsourcing facility Hybrid Pharma of Deerfield Beach, Florida, that sterile compounding violations made its drugs adulterated and unapproved.

    High risk
  17. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warns Empower Pharmacy its compounded drugs missed outsourcing-facility conditions, including labeling and adverse-event reporting.

    Medium
  18. Toyobo Co. Ltd.

    FDA warned Toyobo after inspection found unresolved particulate contamination and environmental monitoring data manipulation affecting sterile injectable drugs.

    High risk